TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 28nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 31nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 36nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 37nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 39nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 45nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 52nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 75nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 114nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 140nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 170nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 236nMAssay Description:Inhibition of binding of radioligand [125I]-PYY to the human Neuropeptide Y receptor type 5, using a stably transfected HEK293 cell lineMore data for this Ligand-Target Pair